Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study |
| |
Authors: | Eckel Florian Lersch Christian Assmann Gerald Schulte-Frohlinde Ewert |
| |
Institution: |
a Department of Internal Medicine II, Technical University of Munich, Munich, Germany |
| |
Abstract: | The antitumor activity of gemcitabine is not dose-response related but schedule-dependent. Based on the results of a published phase I study in patients with non-small-cell lung cancer we started a pilot study of a 24-hr infusion of gemcitabine in patients with adenocarcinoma of the pancreas and biliary tract cancer. Twenty-five patients were enrolled and received a 24-hr infusion of gemcitabine once weekly on three consecutive out of 4 weeks. Dose levels of gemcitabine ranged from 100 to 150 mg/m2. One of 13 chemotherapy-naive patients had a partial response. Dose-limiting toxicity (DLT) was thrombocytopenia in pretreated patients and neutropenia in chemotherapy-naive patients. Other toxicities were oral mucositis, fever, flu-like symptoms, and asthenia. Maximum tolerated dose (MTD), especially in pretreated patients, was 100 mg/m2. |
| |
Keywords: | Gemcitabine 24-hr infusion Prolonged infusion Pancreatic cancer Biliary tract cancer Toxicity |
本文献已被 InformaWorld PubMed 等数据库收录! |